DART (NCI/SWOG S1609): Comprehensive Final Results from Dual Checkpoint Inhibition with CTLA-4 and PD-1 Blockade in Rare Cancers
{{output}}
Background: We summarize final results of the NCI/SWOG S1609 trial, whose objective was to evaluate efficacy signals across 53 refractory rare cancer cohorts treated with dual CTLA-4 and PD-1 inhibition. ... ...
